Crestor Related Published Studies
Well-designed clinical trials related to Crestor (Rosuvastatin)
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. [2009.10]
A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events - Reduction of Cholesterol to Key European Targets Trial. [2009.09.09]
Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. [2009.07]
Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. [2009.07]
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. [2009.06]
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. [2009.06]
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. [2009.06]
The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). [2009.05]
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. [2009.05]
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. [2009.04.30]
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. [2009.04.04]
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. [2009.04.02]
Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. [2009.04]
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. [2009.04]
Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. [2009.04]
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. [2009.04]
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. [2009.04]
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. [2009.03.17]
Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. [2009.03]
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. [2009.03]
Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. [2009.03]
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. [2009.02.15]
Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein. [2009.01]
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. [2009.01]
Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. [2008.12]
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. [2008.12]
Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. [2008.12]
[JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein] [2008.12]
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. [2008.11.20]
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. [2008.11]
[Influence of rosuvastatin in endothelial function and oxidative stress, in patients with acute coronary syndrome] [2008.10]
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. [2008.09]
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. [2008.08.19]
Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. [2008.08]
Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. [2008.08]
Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). [2008.08]
Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia. [2008.07.26]
Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. [2008.07]
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. [2008.04.21]
The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. [2008.04]
Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. [2008.04]
Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. [2008.03]
The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. [2008.03]
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. [2008.03]
Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. [2008.03]
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. [2008.02.01]
Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. [2008.02]
Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. [2008.02]
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. [2008.01.14]
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. [2008]
Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. [2008]
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. [2008]
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. [2008]
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). [2007.12]
Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. [2007.12]
Rosuvastatin in older patients with systolic heart failure. [2007.11.29]
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. [2007.11.01]
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). [2007.10.15]
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. [2007.10]
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. [2007.10]
Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. [2007.08.18]
Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. [2007.07]
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). [2007.06.01]
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. [2007.06]
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. [2007.05]
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)] [2007.04]
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. [2007.03.28]
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. [2007.03.01]
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). [2007.03.01]
Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. [2007.02.11]
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. [2006.10]
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). [2006.09.15]
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. [2006.06.01]
Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. [2006.06]
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). [2006.06]
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. [2006.05]
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. [2006.04]
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. [2006.03]
Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention? [2006.01.16]
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in african-american patients in a six-week trial. [2006.01.15]
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. [2005.11.01]
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. [2005.10]
Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. [2005.10]
Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). [2005.09]
Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. [2005.09]
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin. [2005.08]
Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. [2005.08]
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). [2005.06.01]
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. [2005.06]
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. [2005.02.01]
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. [2005.02]
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. [2005.01.15]
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. [2004.11]
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. [2004.11]
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. [2004.10]
Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. [2004.09]
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. [2004.09]
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. [2004.08]
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. [2004.07.15]
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. [2004.07]
Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study. [2004.05]
|
